Summary: Glutamate receptors (GluRs) are the most common excitatory neurotransmitter receptors in the central nervous system (CNS). These receptors play key roles in synapse formation, learning, memory, neuronal plasticity, epilepsy and neurodegenerative disease processes.The analysis of the molecular organisation, interactions and distribution of native GluRs in the CNS fundamentally depend on well-validated antibodies. While large numbers of anti-GluR antibodies are available and these are extensively used in a range of experimental approaches, investigators have to navigate through a complex system to find out which particular antibodies are appropriate for a specific experiment.At present, there is no universal validation for antibodies. An antibody that works in one system may perform poorly in other. Therefore researchers need to understand how these antibodies have been produced and characterised to determine whether they will work in the assay they intend to perform.There is a growing need for high quality anti-GluR antibodies and stronger validation data. This webinar will review the advantages and limitations of different strategies applied for the production and testing of anti-GluR antibodies for various applications and suggest assessment criteria for a more standardised evaluation of the reliability and method specificity of anti-GluR antibodies.- Elek Molnár, MD, PhD, FHEA